Skip Navigation



Hum. Reprod. Advance Access published online on November 26, 2004
Human Reproduction, doi:10.1093/humrep/deh601
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/2/359    most recent
deh601v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Huirne, J. A.F.
Right arrow Articles by Lambalk, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huirne, J. A.F.
Right arrow Articles by Lambalk, C. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received February 5, 2004
Revised July 21, 2004
Accepted October 15, 2004

Article

Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy

Judith A.F. Huirne 1, Andre C.D. van Loenen 1, Roel Schats 1, Joseph McDonnell 1, Peter G.A. Hompes 1, Joop Schoemaker 1, Roy Homburg 1, and Cornelis B. Lambalk 1*

1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre (VUMC), Amsterdam, The Netherlands

* To whom correspondence should be addressed.
Cornelis B. Lambalk, E-mail: cb.lambalk{at}vumc.nl


  Abstract

BACKGROUND: An optimal range of LH concentrations for achieving pregnancy has not been established. The aim of this study was to investigate the effect of various LH levels induced by different GnRH antagonist doses on IVF outcome. METHODS: This was a prospective, single centre study including 144 IVF patients, stimulated with recombinant FSH from cycle day 2, and co-treated with daily GnRH antagonist (antide/Iturelix) (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml) from cycle day 7 onwards. Serum samples were taken three times daily. RESULTS: Clinical pregnancies were only observed within a particular range of change in LH levels. The upper and lower thresholds for the mean LH area under the curve (AUC), adjusted for the baseline LH level before the antagonist was started (LH AUC-S6; S6=stimulation day 6) were -2.2 and 12.4 (IU/l) respectively (a negative value=below baseline levels). There were no clinical pregnancies outside these threshold values. Similar results were found for progesterone, the threshold levels of progesterone AUC-S6 were 3.98 and -1.21 ng/ml. Moreover, there were no pregnancies with progesterone levels >0.26 ng/ml/follicle on the day of hCG. CONCLUSIONS: Excessive or insufficient suppression of LH and progesterone levels during GnRH antagonist administration and high progesterone/follicle on hCG day seems to be associated with impaired clinical pregnancy rates.

Keywords: GnRH antagonist; IVF; implantation; LH; progesterone.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
S. Kol and R. Homburg
Change, change, change: hormonal actions depend on changes in blood levels
Hum. Reprod., May 1, 2008; 23(5): 1004 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol
Hum. Reprod., January 1, 2007; 22(1): 109 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
I. E. Messinis
Ovarian feedback, mechanism of action and possible clinical implications
Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, J.N. Hugues, C. Pirard, F. Fischl, J.C. Sage, J.L. Pouly, A. Obruca, D.M. Braat, A.C.D. van Loenen, and C.B. Lambalk
Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
Hum. Reprod., June 1, 2006; 21(6): 1408 - 1415.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.